140 related articles for article (PubMed ID: 23134035)
1. [Measurement of minimal residual disease and its implication].
Tsurusawa M; Hori T
Nihon Rinsho; 2012 Apr; 70 Suppl 2():731-6. PubMed ID: 23134035
[No Abstract] [Full Text] [Related]
2. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
Feng JH; Xu XJ; Tang YM
Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
[No Abstract] [Full Text] [Related]
3. Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.
Hokland P; Cotter F
Br J Haematol; 2013 Aug; 162(4):429-30. PubMed ID: 23772825
[No Abstract] [Full Text] [Related]
4. Monitoring minimal residual disease in pediatric hematologic malignancies.
Campana D
Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
[No Abstract] [Full Text] [Related]
5. A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations.
Dvorakova D; Lengerova M; Pospisilova J; Palasek I; Mayer J
Leukemia; 2009 Apr; 23(4):793-6. PubMed ID: 18830256
[No Abstract] [Full Text] [Related]
6. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Haferlach C; Haferlach T; Schnittger S
Cancer; 2008 Jan; 112(1):4-16. PubMed ID: 18000811
[TBL] [Abstract][Full Text] [Related]
7. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
[TBL] [Abstract][Full Text] [Related]
8. Development of minimal residual disease-directed therapy in acute myeloid leukemia.
Freeman SD; Jovanovic JV; Grimwade D
Semin Oncol; 2008 Aug; 35(4):388-400. PubMed ID: 18692689
[TBL] [Abstract][Full Text] [Related]
9. [Detection of minimal residual disease in leukemia using flow cytometry].
Muroi K
Rinsho Ketsueki; 2008 Jun; 49(6):397-407. PubMed ID: 18646607
[No Abstract] [Full Text] [Related]
10. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods.
Zwick D; Cooley L; Hetherington M
Lab Hematol; 2006; 12(2):75-81. PubMed ID: 16751134
[TBL] [Abstract][Full Text] [Related]
11. [Immunophenotyping in acute leukemia: detection of minimal residual disease].
Pálóczi K; Nahajevszky S; Jakab K; Regéczy N; Gopcsa L; László E; Földi J
Orv Hetil; 2000 Nov; 141(46):2487-92. PubMed ID: 11126681
[TBL] [Abstract][Full Text] [Related]
12. The detection and significance of minimal residual disease in acute and chronic leukemia.
Chung NG; Buxhofer-Ausch V; Radich JP
Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
[TBL] [Abstract][Full Text] [Related]
13. [Detection of minimal residual leukemia using polymerase chain reaction method].
Naoe T
Rinsho Byori; 1996 Jun; 44(6):535-40. PubMed ID: 8752731
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease detection by flow cytometry.
Ludwig WD
Lab Hematol; 2004; 10(3):169. PubMed ID: 15529435
[No Abstract] [Full Text] [Related]
15. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Dominietto A
Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
[TBL] [Abstract][Full Text] [Related]
17. Determination of minimal residual disease in leukaemia patients.
Campana D
Br J Haematol; 2003 Jun; 121(6):823-38. PubMed ID: 12786792
[No Abstract] [Full Text] [Related]
18. The minimal residual disease concept coming of age - now for the direct comparison of methodologies.
Ommen HB; Roug AS; Hokland P
Leuk Res; 2012 Apr; 36(4):392-3. PubMed ID: 22261230
[No Abstract] [Full Text] [Related]
19. NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia.
Meyerson HJ; Blidaru G; Edinger A; Osei E; Schweitzer K; Fu P; Ho L
Am J Clin Pathol; 2012 Jan; 137(1):39-50. PubMed ID: 22180477
[TBL] [Abstract][Full Text] [Related]
20. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
Stone RM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
